5-Lipoxygenase deficiency prevents respiratory failure during ventilator-induced lung injury by Caironi, P. et al.
5-Lipoxygenase Deficiency Prevents Respiratory Failure
during Ventilator-induced Lung Injury
Pietro Caironi, Fumito Ichinose, Rong Liu, Rosemary C. Jones, Kenneth D. Bloch, and Warren M. Zapol
Department of Anesthesia and Critical Care, and the Cardiovascular Research Center of the Department of Medicine, Massachusetts General
Hospital, Harvard Medical School, Boston, Massachusetts
Rationale: Mechanical ventilation with high VT (HVT) progressively
leads to lung injury and decreased efficiency of gas exchange. Hyp-
oxic pulmonary vasoconstriction (HPV) directs blood flow to well-
ventilated lung regions, preserving systemic oxygenation during
pulmonary injury. Recent experimental studies have revealed an
important role for leukotriene (LT) biosynthesis by 5-lipoxygenase
(5LO) in the impairment of HPV by endotoxin.Objectives: To investi-
gate whether or not impairment of HPV contributes to the hypo-
xemia associated with HVT and to evaluate the role of LTs in
ventilator-induced lung injury. Methods: We studied wild-type and
5LO-deficient mice ventilated for up to 10 hours with low VT (LVT)
orHVT. Results: Inwild-typemice,HVT, butnot LVT, increasedpulmo-
nary vascular permeability and edema formation, impaired systemic
oxygenation, and reduced survival. HPV, as reflected by the increase
in left pulmonary vascular resistance inducedby leftmainstembron-
chus occlusion, was markedly impaired in animals ventilated with
HVT. HVT ventilation increased bronchoalveolar lavage levels of LTs
and neutrophils. In 5LO-deficient mice, the HVT-induced increase
of pulmonary vascular permeability and worsening of respiratory
mechanics were markedly attenuated, systemic oxygenation was
preserved, and survival increased. Moreover, in 5LO-deficient mice,
HVT ventilation did not impair the ability of left mainstem bronchus
occlusion to increase left pulmonary vascular resistance. Administra-
tion ofMK886, a 5LO-activity inhibitor, orMK571, a selective cysteinyl-
LT1 receptor antagonist, largely prevented ventilator-induced lung
injury. Conclusions: These results indicate that LTs play a central
role in the lung injury and impaired oxygenation induced by HVT
ventilation.
Keywords: hypoxic pulmonary vasoconstriction; leukotrienes; ventilator-
induced lung injury
Excessive stretching of lung parenchyma, by ventilation with
large Vt, progressively injures the structure and gas-exchanging
efficiency of the lung (1–3). Common alterations of the respira-
tory system during ventilator-induced lung injury (VILI) include
pulmonary edema, because of increased permeability of the
alveolar–capillary membrane, and hypoxemia, as a consequence
of intrapulmonary right-to-left shunting (especially in the termi-
nal stages of VILI). During the development of acute lung injury,
systemic oxygenation is maintained by hypoxic pulmonary vaso-
constriction (HPV), a physiologic property of the pulmonary
microvasculature that diverts blood flow from hypoxic/poorly
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ventilated lung regions toward more normally ventilated lung
regions. Experimental and clinical studies have reported that
HPV is impaired in lung injury induced by endotoxemia (4, 5)
and in patients affected by acute respiratory distress syndrome
(ARDS) (6). However, whether or not impairment of HPV
contributes to the hypoxemia associated with VILI has not been
reported.
The mechanisms contributing to the development of VILI
have been extensively investigated (7). Excessive lung inflation
can produce mechanical disruption of the alveolar–capillary
membrane (“capillary stress failure”) (8–10). In addition, the
repetitive opening and closing of alveoli, especially in diseased
lung regions, can contribute to the injury (11). Moreover, many
studies have provided evidence that high Vt ventilation (HVt)
can induce lung inflammation via neutrophil infiltration and the
production of inflammatory cytokines (12–17).
Leukotrienes (LTs) are potent lipid mediators of inflamma-
tion (18). The first step for LT biosynthesis requires the enzyme
5-lipoxygenase (5LO), which, in the presence of 5LO-activating
protein (FLAP), converts arachidonic acid into LTA4. An unsta-
ble intermediate, LTA4 is metabolized by LTA4 hydrolase into
LTB4 or, alternatively, is conjugated with glutathione by LTC4
synthase to produce the cysteinyl-LTs (cysLTs), LTC4, LTD4,
andLTE4. LTB4 acts as a powerful chemokinetic and chemotactic
agent for leukocytes (19). CysLTs increase vascular permeability
and modulate vascular smooth muscle tone (18) through the
activation of the cysLT1 and cysLT2 receptors (20, 21).
LTs have been implicated as inflammatory mediators in ex-
perimental models of acute lung injury (22) and were found to
be elevated in pulmonary edema fluid obtained from patients
with ARDS (23–25). Moreover, cysLTs appear to play a critical
role in mediating neutrophil-dependent inflammation (26). Re-
cently, we reported that LTs contribute to the impairment of
HPV associated with endotoxin-induced lung injury (27). This
article describes a newly developed murine model of lung injury
induced by long-term mechanical ventilation (up to 10 hours)
and reports the impact of HVt ventilation on the pulmonary
vasoconstrictor response to alveolar hypoxia and the role of LTs
in the pathogenesis of VILI. The results presented in this article
have been previously reported, in part, in the form of abstracts
(28, 29).
METHODS
Mouse Model of VILI
Mice were anesthetized by intraperitoneal injection of ketamine
(120 mg/kg) and xylazine (8 mg/kg); then, a tracheostomy and arterial
catheterization were performed as previously described (27). Mice re-
ceived two differing types of mechanical ventilation. Low Vt (LVt)
ventilation provided a Vt equal to 12% of inspiratory capacity (IC),
at a respiratory rate of 100 breaths/minute. HVt ventilation provided
a Vt equal to 43% of IC, at a respiratory rate of 90 breaths/minute.
IC was obtained, for each animal, by constructing a pressure–volume
(PV) curve of the respiratory system. Mechanical ventilation was ended
either after 10 hours or when (after 7–10 hours of HVt ventilation) a
severe deterioration of the respiratory system compliance was detected
by monitoring the PV curve, representing a preterminal state.
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Gas Exchange Analysis
At the end of each experiment, arterial blood was obtained from the
left carotid artery, and a blood gas analysis was performed.
Bronchoalveolar Lavage Fluid Analysis
Bronchoalveolar lavage was performed using 5  1 ml phosphate-
buffered saline. CysLTs and LTB4 concentrations in bronchoalveolar
lavage fluid (BALF) supernatants were measured using an enzyme
immunoassay (Neogen Corporation, Lexington, KY) after lipid extrac-
tion. The total number of cells obtained fromBALF after centrifugation
was counted with a hemocytometer, and a differential leukocyte count
was measured after staining with Hema 3 (Fisher Scientific, Pittsburgh,
PA).
Lung Edema and Microvascular Permeability Assay
To assess pulmonary edema, the amount of extravascular lung water
(EVLW) in lung tissue was computed at the end of the experiment for
the right lung as described previously (30). To estimate pulmonary
vascular permeability, BALF supernatant was analyzed for total protein
concentration using the Bradford method (Bio-Rad, Hercules, CA).
Histopathologic Analysis
Mouse lungs were perfusion-fixed via both the airway and pulmonary
artery and embedded in JB-4 resin. Sections 2-m thick were stained
with 0.05% toluidine blue and microscopically examined by an investi-
gator blinded as to the mouse genotype and ventilation protocol.
Measurement of HPV
After 6 hours of either LVt or HVt ventilation, mice were ventilated
in a standard fashion with a Vt of 7 ml/kg body weight and a respiratory
rate of 100 breaths/minute. After a thoracotomy was performed, sys-
temic arterial pressure (SAP), pulmonary arterial pressure, and left
pulmonary arterial blood flowwere continuously recorded as previously
described (27). To assess HPV, the percentage increase in left pulmo-
nary vascular resistance (LPVR) induced by left lung alveolar hypoxia
(caused by left mainstem bronchus occlusion) was computed for each
animal.
Pulmonary Vascular Response to Angiotensin II
To assess pulmonary vasomotor activity after mechanical ventilation,
pulmonary vascular resistance was measured before and after intrave-
nous infusion of angiotensin II (5 g/kg/minute) as previously described
(31). To examine the effect of angiotensin II on HPV, LPVR changes
induced by left lung alveolar hypoxia were measured before and after
angiotensin II infusion.
Statistical Analysis
Statistical analysis was performed using Sigma Stat 2.03 (SPPS, Inc.,
Chicago, IL). Statistical significance was defined as a p value of less
than 0.05. All data are expressed as mean  SEM.
TABLE 1. VENTILATORY SETTINGS AND RESPIRATORY MECHANICS
Ventilation Strain of VT plet/bw PEEPt,dyn Peak Pressure
Protocol Mice N Body weight (g ) IC (ml) VT/IC (% ) VT (ml) (ml/kg) (cm H2O ) (cm H2O )
LVT WT 25 23.0  0.4 1.54  0.02* 12 0.18  0.00 11  0 2.1  0.1* 9.2  0.1
HVT WT 28 23.4  0.3 1.56  0.03* 43 0.67  0.01*† 25  0*† 1.8  0.1*† 21.9  0.4†
LVT 5LO/ 17 22.4  0.2 1.73  0.03 12 0.21  0.00 12  0 2.5  0.1 8.9  0.1
HVT 5LO/ 16 22.3  0.2 1.71  0.03 43 0.74  0.01† 30  0† 2.3  0.1 22.7  0.3†
LVT MK886 14 22.8  0.4 1.60  0.04* 12 0.19  0.00 11  0 2.2  0.1 9.8  0.1
HVT MK886 17 22.9  0.3 1.55  0.02* 43 0.67  0.01*† 25  0*† 1.6  0.1*† 21.8  0.5†
HVT MK571 11 23.4  0.5 1.59  0.03 43 0.69  0.02† 25  1*† 1.5  0.1* 23.4  0.5†
Definition of abbreviations: bw  body weight; IC  inspiratory capacity; 5LO  5-lipoxygenase; MK571  wild-type mice treated with MK571; MK886  wild-type
mice pretreated with MK886; PEEPt,dyn  total dynamic positive end-expiratory pressure; VT plet actual delivered VT estimated by plethysmographic measurements;
WT  wild-type.
Respiratory mechanics at baseline in mice that were subsequently ventilated at LVT or HVT. All values were compared between different ventilation strategies and
genotype/treatment groups by analysis of variance with a post hoc comparison.
* p  0.05 versus 5LO-deficient mice with the same ventilation strategy.
† p  0.01 versus LVT ventilation in the same genotype/treatment group and LVT ventilation in WT mice.
Additional details on the methods used in these studies and a de-
tailed description of experimental groups studied are provided in the
online supplement.
RESULTS
Effects of HVT Ventilation in Wild-Type Mice
We developed a murine model of VILI, in which mice were
subjected to long-term mechanical ventilation with either LVt
or HVt (Table 1). Mechanical ventilation was ended either after
10 hours or when (after 7–10 hours of HVt ventilation) a severe
deterioration of respiratory system compliance was detected by
monitoring the PV curve (representing a preterminal state).
Hemodynamic parameters did not change during mechanical
ventilation and were similar in mice ventilated at a LVt or HVt
(see Table E1 on the online supplement). Similarly, the acid-
base status did not differ between the two groups of ventilated
mice and remained unchanged throughout the experiment (see
Table E2). Mice ventilated at LVt routinely survived for the 10-
hour study period. In contrast, mice ventilated at HVt consis-
tently survived only until the 7th hour. Thereafter, they progres-
sively developed severe acute lung injury and, by the 10th hour
of ventilation, only 20% of the mice remained alive (Figure 1).
PV curves of the respiratory system were generated before
and every hour during LVt or HVt ventilation. During HVt
ventilation, lung compliance decreased, as reflected by a down-
ward and rightward shift of the PV curve (Figure 2B), whereas
during the entire period of LVt ventilation, the PV curve re-
mained unchanged (Figure 2A). At the end of the experiment,
EVLW was markedly greater in mice ventilated at HVt (6.1 
0.5 g H2O/g dry lung) than in mice ventilated at LVt or mice
studied at baseline (3.0 0.2 and 3.2 0.2, respectively; p 0.01
for both; Figure 3A). After 6 hours of mechanical ventilation, the
permeability of the alveolar–capillary membrane, as reflected
by the total protein concentration in BALF, was similar between
the HVt and LVt group (Figure 3B). In contrast, after longer
periods of mechanical ventilation (up to 10 hours), BALF total
protein concentration from mice ventilated at HVt was greater
than that obtained from mice ventilated at LVt (Figure 3B), dem-
onstrating that prolonged HVt ventilation markedly increases
the permeability of the murine alveolar–capillary membrane.
The systemic PaO2 and the alveolar–arterial oxygen tension
difference (a-aDo2) did not change during LVt ventilation (see
Table E2 and Figure 3A, respectively), whereas HVt ventilation
markedly decreased the PaO2 (p  0.001; see Table E2 in the
online supplement) and doubled the a-aDo2 (p  0.01; Figure
3A) at the end of the experiment. The increase inEVLWinduced
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Figure 1. Survival during long-term mechanical ventilation in wild-type
(WT) mice, during low VT (LVT; n  12) or high VT (HVT; n  15)
ventilation, and in 5-lipoxygenase (5LO)–deficient mice (n  8) and in
MK886-pretreated WTmice (n 12) during HVT ventilation (*p 0.01
vs. other groups).
by HVt ventilation was highly correlated with the decrease in
PaO2 and the increase in a-aDo2 (r
2  0.91 and r2  0.86, respec-
tively; p  0.05 for both).
To assess the histopathologic consequences of mechanical
ventilation in our murine model of VILI, lung sections were
prepared from mice ventilated at LVt or HVt and examined
microscopically. In comparison tomice ventilated at LVt (Figure
4A) and mice studied at baseline (data not shown), the alveolar–
capillary membrane in the central lung regions from mice sub-
jected to HVt was thin and lacked a patent capillary network,
associated with epithelial surface disruption and a moderate
Figure 2. The pressure–volume (PV) curve of the
respiratory system in WT mice ventilated either
(A ) at LVT (n  12) or (B ) at HVT (n  15), and
in (C ) 5LO-deficient mice (5LO/; n  8) and
(D )MK886-pretreatedWTmice (MK886; n 12),
during mechanical ventilation with HVT. Solid cir-
cles represent PV curve performed at baseline,
open circles represent PV curve performed after 1
hour of ventilation, inverted solid triangles after 2
hours, inverted open triangles after 3 hours, solid
squares after 4 hours, open squares after 5 hours,
solid diamonds after 6 hours, open diamonds after
7 hours, solid hexagons after 8 hours, open triangles
after 9 hours, and solid triangles represent PV curve
performed at the end of the experiment. For clar-
ity, onlymean values are reported. PV curve values
obtained at the end of the experiment represent
mean values of the last PV curve performed in each
animal (either after 10 hours of LVT ventilation or
after a period between 7 and 10 hours of HVT
mechanical ventilation). *p  0.05 versus base-
line; #p  0.05 versus WT mice ventilated at LVT
and 5LO-deficient and MK886-pretreated WT
mice ventilated at HVT at the end of the experi-
ment. IC  inspiratory capacity of the respiratory
system, defined as the inflation volume needed
to achieve 30 cm H2O airway pressure.
degree of inflammatory cell infiltration (Figure 4B). Lung sub-
pleural regions were less affected as judged by the presence of
open capillaries and less alveolar surface injury (data not shown).
HVT Ventilation Impairs HPV
To assess the impact of HVt ventilation on HPV, changes in
LPVR during left lung alveolar hypoxia were examined in mice
after 6 hours of either LVt or HVt ventilation. To induce left
lung alveolar hypoxia, the left mainstem bronchus was reversibly
occluded with a microvascular clip. Before left mainstem bron-
chus occlusion (LMBO), hemodynamic parameters were similar
between the two groups of ventilated mice (see Table E3). In
mice ventilated at LVt, LMBO consistently decreased left pul-
monary arterial blood flow, resulting in a 99  10% increase in
LPVR (p  0.01; Figure 5). The same magnitude of increase in
LPVR during LMBO was measured in mice studied at baseline
(100 10%), demonstrating that long-term ventilation with LVt
does not affect HPV. In contrast, LMBO did not increase LPVR
in mice ventilated at HVt (17 8%, p not significant vs. HVt
ventilation before LMBO and p 0.01 vs. LVt ventilation after
LMBO; Figure 5). These results show that HVt ventilation im-
pairs HPV.
To examine the possibility that impaired HPV after HVt
ventilation was attributable to a generalized mechanical disrup-
tion of pulmonary vasomotor responsiveness, we studied the
pulmonary vasomotor response to the intravenous infusion of
angiotensin II (5 g/kg/minute) in mice ventilated for 6 hours.
After LVt ventilation, angiotensin II increased pulmonary vas-
cular resistance from 57  15 mm Hg/ml/minute/g to 106 
7 mm Hg/ml/minute/g (p  0.05). Similarly, in mice ventilated
at HVt, pulmonary vascular resistance increased from 64  8
to 125 8 mmHg/ml/minute/g after angiotensin II infusion (p
0.01). To investigate the hypothesis that impairment of HPV
after HVt ventilation is caused by an alteration in the balance
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Figure 3. Extravascular lung water (EVLW) and alveolar–arterial oxygen
tension difference (A-aDO2; A ) and total protein concentration in bron-
choalveolar lavage fluid (BALF; B ) in WT mice subjected to mechanical
ventilation. After long-term mechanical ventilation, EVLW (n  5) and
A-aDO2 (n  15) were increased in mice ventilated with HVT compared
with mice ventilated with LVT (n  3 for EVLW, n  12 for A-aDO2)
and mice studied at baseline (n  3 for EVLW, n  10 for A-aDO2;
*p 0.01). Similarly, the total protein concentration in BALF was higher
in mice after long-term HVT ventilation (n  6) than in mice studied
at baseline (n  4), in mice after long-term LVT ventilation (n  6),
and in mice after ventilation with HVT (n  5) for only 6 hours (*p 
0.001, all groups).
of vasoconstrictors and vasodilators, changes in LPVR induced
by LMBO before and after beginning an angiotensin II infusion
were measured in a subset of mice after mechanical ventilation.
In animals ventilated at HVt, angiotensin II infusion restored
HPV, enhancing the LMBO-induced increase in LPVR to 92 
15% (p  0.05 vs. wild-type mice ventilated at HVt before
angiotensin II infusion), but angiotensin II did not alter HPV
in mice ventilated at LVt (data not shown). Taken together,
these results demonstrate that the impairment ofHPVassociated
withHVt ventilation is not attributable to a generalizedmechan-
ical dysfunction of the vasomotor contractile apparatus, and that
administration of a vasoconstrictor to mice ventilated for 6 hours
at HVt can restore the ability of the pulmonary vasculature to
constrict in response to hypoxia.
HVT Ventilation Induces Pulmonary Neutrophil Recruitment
and LT Production
To examine the mechanisms by which HVt ventilation induces
pulmonary injury and impairs HPV, we measured the levels of
neutrophils in BALF obtained from mice after LVt or HVt
ventilation. Inmice ventilated atHVt, neutrophil levels in BALF
were significantly higher than in mice ventilated with LVt, both
after 6 hours (31  6 vs. 7  2  103, p  0.01) and after the
entire duration of the experiment (27  5 vs. 14  1  103,
p  0.01; see Table E4).
To investigate whether mechanical ventilation induces LT
production, BALF concentrations of cysLTs and LTB4 were
measured. In comparison to mice studied at baseline, long-term
LVt ventilation did not alter the BALF levels of either cysLTs
or LTB4 (Figure 6). In contrast, BALF cysLT levels in mice
receiving HVt ventilation were greater than in mice ventilated
at LVt, both after 6 hours (0.22  0.04 vs. 0.12  0.01 ng/ml,
p 0.01) and after the entire duration of mechanical ventilation
(p 0.01; Figure 6A). BALF LTB4 levels did not differ between
LVt and HVt group after 6 hours of mechanical ventilation
(1.8  0.3 vs. 2.3  0.4 ng/ml). In contrast, after long-term
mechanical ventilation, BALF LTB4 concentrations in mice ven-
tilated at HVt were twofold greater than in mice ventilated at
LVt (p  0.05; Figure 6B).
Congenital Disruption of 5LO Decreases Mortality
and Attenuates VILI
To learn whether or not LTs are involved in the pathogenesis
of VILI, we studied the effects of LVt and HVt ventilation in
mice deficient for 5LO (Table 1). The two genotypes did not
differ in terms of hemodynamic measurements (see Table E1)
and acid-base parameters (data not shown). Mice deficient for
5LO routinely survived during LVt ventilation for the 10-hour
study period. Survival during HVt ventilation was longer in
5LO-deficient than in wild-type mice (p  0.01; Figure 1): 5LO-
deficient mice ventilated at HVt consistently survived for 10
hours. The PV curve of the respiratory system of 5LO-deficient
mice ventilated at HVt for 10 hours was shifted upwards in
comparison with the baseline, as well as in comparison with wild-
type mice ventilated at HVt at the end of the experiment (Figure
2C). Pulmonary microvascular permeability, as reflected by the
BALF total protein concentration, increased in 5LO-deficient
mice during HVt ventilation in comparison to LVt ventilation,
but was less than that in wild-typemice ventilated at HVt (Figure
7A). HVt ventilation did not increase the a-aDo2 of 5LO-defi-
cient mice (90  11 vs. 99  10 mm Hg at baseline), and this
value was markedly less than that of wild-type mice receiving
HVt ventilation (216  19 mm Hg, p  0.001). Similarly, the
PaO2 of 5LO-deficient mice ventilated at HVt did not differ from
the values recorded after LVt ventilation (data not shown) and
was markedly higher than that of wild-type mice receiving HVt
ventilation (p  0.001; Figure 7B). Neutrophil levels in BALF
during HVt ventilation were lower in 5LO-deficient mice than
in wild-type mice, both after 6 hours (Figure 8) and at the end
of the experiment (18  2  103 vs. 27  5  103, p  0.05;
see Table E4). After 10 hours of HVt ventilation, histologic
examination of lung sections from 5LO-deficient mice showed
essentially normal morphology similar to that observed in lungs
of wild-type or 5LO-deficient mice ventilated at LVt and mark-
edly different from that found in wild-type mice ventilated at
HVt (Figure 4).
Preservation of HPV after HVT Ventilation
in 5LO-deficient Mice
To investigate the effects of 5LO deficiency on the impairment
of HPV induced by HVt ventilation, we analyzed the changes
of LPVR induced by LMBO in 5LO-deficient mice ventilated
with either LVt or HVt for 6 hours. Before LMBO, systemic
arterial pressure and pulmonary arterial pressure were similar
in both groups of 5LO-deficient mice and did not differ from
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Figure 4. Lung sections 2-m thick fromWT
mice ventilated at LVT (A ) and HVT (B ), and
from 5LO-deficient mice (C ) and MK886-
pretreated WT mice (D ) both ventilated at
HVT after long-term mechanical ventilation.
Comparable areas from central lung regions
are shown. Note the lacey network of open
capillaries after (A ) LVT ventilation (arrows)
and the loss of these features after (B ) HVT
ventilation (arrows). The narrow alveolar–
capillary membrane after HVT ventilation re-
flects capillary collapse and epithelial surface
disruption.Note also the presence of neutro-
phils within the intravascular space (open
arrow in B ). The absence of these structural
changes in 5LO-deficient mice (C ) and WT
mice pretreated with MK886 (D ) demon-
strates protection against injury induced by
HVT ventilation. Bar 25 m; all other pan-
els are at the samemagnification. Alv alve-
olar space.
wild-type mice in corresponding experimental groups (see Table
E3). In 5LO-deficient mice after LVt ventilation, LMBO de-
creased left pulmonary arterial blood flow, resulting in a 98 
15% increase of LPVR (p  0.01; Figure 5). Similarly, after
5LO-deficient mice were ventilated at HVt, LMBO decreased
left pulmonary arterial blood flow, leading to an increased
LPVR, which was markedly greater than that measured in wild-
type mice (94  9 vs. 17  8%, p  0.001; Figure 5).
Inhibition of 5LO-activating Protein Decreases VILI
Because strain differences in the background of wild-type and
5LO-deficient mice might potentially lead to differing responses
to HVt ventilation (32), we sought to confirm that 5LO defi-
ciency attenuates VILI by studying wild-type mice pretreated
with the FLAP inhibitor MK886 (Calbiochem, San Diego, CA).
Survival during HVt ventilation of MK886-pretreated wild-type
mice did not differ from 5LO-deficient mice and was longer than
that in untreated animals (p  0.01; Figure 1). HVt ventilation
ofMK886-pretreatedwild-typemice shifted the PV curve slightly
downward at low lung inflation volumes, but the shift was less
marked than that caused by HVt ventilation of untreated wild-
type mice (Figure 2D). Pretreatment of wild-type mice with
MK886 prevented the increase in EVLW associated with HVt
ventilation (4.1 0.6 vs. 6.1  0.5 g H2O/g dry lung in untreated
wild-type mice, p 0.05). Moreover, HVt ventilation ofMK886-
pretreated wild-typemice increased BALF total protein concentra-
tion to a lesser extent than was observed in untreated wild-type
mice (Figure 7A). HVt ventilation did not impair gas exchange in
MK886-pretreated mice: the a-aDo2 (data not shown) and PaO2
(Figure 7B) after 10 hours of HVt ventilation were similar to the
values recorded in mice at baseline. Pretreatment with MK886
significantly reduced the pulmonary neutrophil recruitment asso-
ciatedwithHVt ventilation, as reflected by the decreased neutro-
phil levels in BALF obtained from MK886-pretreated wild-type
mice in comparison to untreated animals (Figure 8 and Table
E4). Histopathologic evaluation of lung sections from MK886-
pretreated mice ventilated at HVt showed protection against
VILI to the same extent as that observed in 5LO-deficient mice
(Figure 4). Pretreatment of wild-type mice with MK886 pre-
vented the increase of cysLTs and LTB4 concentrations in BALF
after HVt ventilation (Figure 6). Of note, when wild-type mice
were treated with the vehicle used to dissolve MK886, they mani-
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Figure 5. Effects of congenital deficiency of 5LO on the left mainstem
bronchus occlusion (LMBO)–induced increase in left pulmonary vascular
resistance (LPVR) in mice ventilated at LVT or HVT for 6 hours. In mice
ventilated at LVT, LMBO markedly increased LPVR both in WT (n  8)
and 5LO-deficient mice (n 4). In contrast, after HVT ventilation, LMBO
did not increase LPVR in WT mice (n  8), whereas it did increase LPVR
in 5LO-deficient mice (n  3; *p  0.001 vs. WT mice). NS  not
significant.
fested a similar development of respiratory failure during HVt
ventilation as did untreated wild-type mice (data not shown).
Effects of a CysLT Receptor 1 Antagonist on Lung Injury
Caused by HVT Ventilation
To elucidate the role of cysLTs in the pathogenesis of VILI,
wild-type mice were treated with MK571, a cysLT receptor 1
antagonist (Cayman Chemical, Ann Arbor, MI). In MK571-
treated wild-type mice ventilated at HVt, survival did not differ
from 5LO-deficient or MK886-pretreated wild-type mice and
was longer than that observed in untreatedwild-typemice (100%
survival after 10 hours of HVt ventilation, p  0.01). At the
end of the experiment, total protein concentration in BALF
from MK571-treated wild-type mice was lower than that ob-
tained from untreated animals (Figure 7A) and was similar to
that measured in BALF from 5LO-deficient mice and MK886-
pretreated wild-type mice. Moreover, treatment of wild-type
mice with MK571 prevented the increase in EVLW associated
with HVt ventilation (3.7  0.2 vs. 6.1  0.5 g H2O/g dry lung
in untreated wild-type mice, p  0.05). The PaO2 after HVt
ventilation was greater inMK571-treated than in untreated wild-
type mice (p  0.01) and did not differ from that measured
in 5LO-deficient and MK886-pretreated wild-type mice (Figure
7B). In contrast, pulmonary neutrophil recruitment into BALF
induced by HVt ventilation was not attenuated by MK571 treat-
ment (Figure 8 and Table E4).
DISCUSSION
Our study demonstrates that long-term mechanical ventilation
of mice with HVt induces severe acute lung injury, characterized
by pulmonary inflammation and edema accumulation and by
severely altered gas exchange with evidence of impaired HPV
and systemic arterial hypoxemia, ultimately leading to death.
Congenital deficiency of 5LO markedly attenuates the develop-
ment of acute respiratory failure during HVt ventilation, reduc-
ing lung inflammation and preserving the effectiveness of HPV
Figure 6. Leukotriene (LT) C4/D4/E4 (A ) and LTB4 (B ) levels in BALF
obtained from untreated and MK886-pretreated WT mice after long-
term mechanical ventilation with LVT (n  6, both groups) or HVT (n 
6, both groups) and frommice studied at baseline (n 3, both groups).
Both LTC4/D4/E4 and LTB4 levels were significantly increased in untreated
WT mice after HVT ventilation (*p  0.05 vs. LVT ventilation and base-
line). In contrast, pretreatment with MK886, a 5LO-activating protein
(FLAP) inhibitor, blocked the increase of LT production associated with
HVT ventilation.
and systemic oxygenation. Treatment with the FLAP inhibitor
MK886 or the selective cysLT1 receptor antagonist MK571 re-
duced pulmonary microvascular permeability and edema forma-
tion associated with HVt ventilation and maintained systemic
oxygenation to the same extent as did congenital 5LO deficiency.
These findings suggest an important role for LTs, particularly
cysLTs, in the pathogenesis of VILI.
In contrast to previous studies, both in mice (14–16, 33) and
other species (2, 7, 34), in which VILI was investigated after
exposure to mechanical ventilation for shorter periods of time or
without producing severe lung injury, our animal model enabled
exposure of mice to mechanical ventilatory stress until fatal
respiratory failure was produced. This design permitted us to
investigate the impact on survival of different ventilation strate-
gies and potential treatments and to characterize the sequence
of events that contribute to the pathophysiology of murine VILI.
Mice were ventilated at HVt for a maximal period of 10 hours.
To have a reproducible severity and time course of the develop-
ment of the lung injury, Vtwas set in each animal as a percentage
of the IC of the respiratory system (35). From pilot studies, we
learned that mechanical ventilation with a Vt near 40% of IC
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Figure 7. Total protein concentration in BALF (A ) and PaO2 (B ) in un-
treatedWTmice, 5LO-deficient mice, andWTmice treated withMK886
or MK571 after prolonged ventilation. Total protein concentration in
BALF at the end of the experiment (A ) was markedly higher in untreated
WT mice ventilated at HVT (n  6) than in WT mice ventilated at LVT
(n  6). Congenital deficiency of 5LO (n  5) and treatment with
MK886 (n  6) or MK571 (n  3) significantly reduced the increase
in BALF total protein concentration caused by HVT ventilation (*p 
0.05, **p  0.01 vs. LVT ventilation). PaO2 (B ) markedly decreased in
untreated WT mice after HVT ventilation (n  10 at baseline, n  5 at
6 hours, and n  15 at the end of the experiment). In contrast, PaO2
remained unchanged during HVT ventilation in 5LO-deficient mice
(n  7 at baseline, n  5 at 6 hours, and n  8 at the end of the
experiment), in MK886-pretreated WT mice (n  6 at baseline, n  5
at 6 hours, and n  12 at the end of the experiment), and in MK571-
treated WT mice (n 5 at 6 hours, n 6 at the end of the experiment).
produced severe lung injury after 6 to 7 hours of ventilation. In
contrast, Vt set according to the body weight of the animals led
to a greater variability of the severity and the time of onset of
severe lung injury. For LVt ventilation, Vt was set equal to 12%
of IC. In an attempt to examine only the variation of Vt, a
similar respiratory rate was used for both ventilatory strategies
(100 and 90 breaths/minute during LVt and HVt ventilation,
respectively). Because of the marked difference of minute venti-
lation between the LVt and HVt group, different fractions of
carbon dioxide were added to the inspiratory gas mixture to
maintain PaCO2 within a physiologic range. Thus, we were able
to avoid respiratory acidosis or alkalosis, which might influence
Figure 8. Neutrophil levels in BALF obtained from untreated WT mice,
5LO-deficient mice, and WT mice treated with MK886 studied at base-
line (n  4, each group) and after 6 hours of LVT or HVT ventilation
(n  5, each group), and from MK571-treated WT mice ventilated at
HVT for 6 hours. HVT ventilation significantly increased neutrophil levels
only in untreated WT and in MK571-treated WT mice (**p  0.001 vs.
baseline and LVT ventilation, *p  0.05 vs. 5LO-deficient and MK886-
pretreated WT mice ventilated at HVT). Congenital deficiency of 5LO
and pretreatment with MK886 prevented the increased levels of neutro-
phils in BALF associated with HVT ventilation (p  0.001 vs. untreated
WT mice).
the production of inflammatory mediators and the pathophysiol-
ogy of acute lung injury (36–38).
Small animals have been reported to require a shorter period
of time to developVILI (as short as 1 hour) (2) than larger animals
(24–48 hours) (3), suggesting that mechanical stress–driven injury
predominates in small animals, whereas inflammation-induced
injury has a more important role in larger animals (7). In the
present study, the survival time during HVt ventilation was sig-
nificantly longer than that previously reported in rodents (7, 33).
Moreover, wild-type mice were ventilated with an HVt of approxi-
mately 25 ml/kg, generating a peak airway pressure of 22 cm H2O
(Table 1), a lung stretch of milder intensity than was produced
in previous murine models of VILI (14, 16, 33). Of note, the
deterioration of the respiratory system during HVt ventilation
was preceded by pulmonary neutrophil and cysLT accumulation.
These findings support the hypothesis that HVt ventilation in-
duces murine lung injury, at least partially, mediated and ampli-
fied by inflammation, as recently suggested (14–16). It is con-
ceivable that VILI develops as a result of a wide spectrum of
mechanisms, in which two extremes may be recognized (39):
short-term VILI, induced by higher stretch/Vt with a predomi-
nance of mechanical stress–induced mechanisms, and long-term
VILI, induced by a milder stimulus leading to inflammation-
induced mechanisms of lung injury.
Because a deterioration of arterial oxygenation is frequently
observed in association with severe VILI, and because HPV
serves to prevent the systemic hypoxemia associated with alveo-
lar edema and intrapulmonary shunting, we investigatedwhether
HVt mechanical ventilation itself could alter the pulmonary
vasoconstrictor response to alveolar hypoxia.We chose to exam-
ine the effect of alveolar hypoxia on HPV before the develop-
ment of pulmonary edema, which typically commences after
6 hours of HVt ventilation. In wild-type mice ventilated at HVt,
LMBO did not significantly increase the LPVR, consistent with
a severe impairment of HPV. This impairment did not occur
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with LVt ventilation. To our knowledge, these findings demon-
strate for the first time that the decreased gas exchange efficiency
associated with VILI is caused not only by the accumulation of
lung edema but also by inhibiting the ability of the pulmonary
circulation to divert blood flow from hypoxic/poorly ventilated
to well-ventilated lung regions. Of note, at the time of HPV
assessment, arterial oxygenation remained preserved, likely be-
cause alveolar edema was not yet present, as suggested by our
analysis of BALF total protein concentration.
The impairment of HPV was unlikely to be caused by me-
chanical disruption of the pulmonary vascular contractile appara-
tus induced by high-stretch/Vt ventilation. The observation that
angiotensin II induced a similar increase of pulmonary vascular
resistance both in mice ventilated at LVt and HVt clearly dem-
onstrates the preservation of vascular reactivity to an exogenous
agonist. Intravenous infusion of angiotensin II also restoredHPV
after HVt ventilation. HPV is considered an intrinsic property
of pulmonary vascular smooth muscle cells that is modulated by
vasoactive mediators (40). The magnitude of HPV at any time
results from the balance between vasodilating and vasoconstrict-
ing factors (31). Thus, HVt ventilation is likely to alter the levels
of vasodilators and vasoconstrictors, favoring vasodilation and
impairing HPV. The infusion of angiotensin II is likely to have
readjusted the balance toward vasoconstriction, thereby restor-
ing HPV.
Enhanced levels of both LTB4 and cysLTs were detected in
BALF obtained from mice after HVt mechanical ventilation, in
comparison with mice after LVt ventilation and animals studied
at baseline. LT concentrations have been reported to be elevated
in other experimental models of acute lung injury (22, 27). More-
over, increased levels of LTs have been detected in pulmonary
edema fluid obtained from patients with ARDS (23–25). LTs
are primarily synthesized by activated cells of myeloid origin,
such as neutrophils, eosinophils, mast cells, and monocytes/mac-
rophages (26). It has been demonstrated, both in animal models
(7, 14) and patients withARDS (41), that high stretch/Vt ventila-
tion can induce activation and pulmonary recruitment of neutro-
phils and alveolar macrophages. We found that HVt ventilation
induced pronounced neutrophil accumulation in BALF both
after 6 hours of ventilation and at the end of the study. It is
probable that HVt ventilation recruits/activates myeloid cells
responsible for pulmonaryLTbiosynthesis. Increased concentra-
tion of LTs, particularly the chemoattractant LTB4, may recruit
additional leukocytes, thereby amplifying the inflammatory re-
sponse to HVt. Taken together, these findings led us to hypothe-
size a role for LTs in the pathogenesis of VILI.
Congenital disruption of 5LO or pretreatment with the FLAP
inhibitor MK886 during HVt ventilation significantly preserved
respiratory mechanics and prevented the increase of alveolar–
capillary membrane permeability. Systemic arterial oxygenation
was maintained, and survival was increased. Because products
of the 5LO pathway, especially cysLTs, are vasoactive mediators
(18) and have been previously implicated in the impairment of
HPV induced by endotoxemia (27), we investigated the role of
5LO in the impairment of HPV associated with VILI. We found
that 5LO-deficient mice were protected from the deleterious
effects of HVt ventilation on HPV. Thus, it is possible that the
production of LTs associated with HVt ventilation alters the
balance of vasodilators and vasoconstrictors regulating pulmo-
nary vascular tone in wild-type mice, leading to an impaired
HPV. Although other vasoactive mediators produced during
HVt ventilation may contribute to the loss of HPV, such as
nitric oxide (42) or prostacyclin (13), our results suggest that
activation of 5LO is required to impair HPV during the develop-
ment of VILI.
The reduction in lung neutrophil accumulation in 5LO-deficient
and in MK886-pretreated wild-type mice ventilated at HVt
suggests a possible role for the chemoattractant LTB4 in neutro-
phil recruitment associated with VILI. Despite preventing the
ventilator-induced pulmonary accumulation of leukocytes mea-
sured after 6 hours of ventilation, 5LO-deficient mice and
MK886-pretreated wild-type mice showed increased BALF neu-
trophil levels after more prolonged HVt ventilation, albeit to a
lesser extent than was observed in wild-type mice. It is conceiv-
able that additional LT-independent mechanisms, such as the
recently described activation of the chemokine receptor CXCR2
(14), contribute to the pulmonary accumulation of leukocytes
during VILI.
Because increased concentrations of cysLTs were detected
in BALF from mice ventilated at HVt before the development
of lung injury, we studied the effects of treatment with MK571,
a selective cysLT1 receptor antagonist, during HVt ventilation.
Treatment of wild-typemice withMK571 reduced BALF plasma
protein concentration to the same extent as was measured in
5LO-deficient and MK886-pretreated wild-type mice. In addi-
tion, MK571-treated wild-type mice ventilated at HVt did not
develop pulmonary edema, and survival was enhanced to a simi-
lar extent as that observed for 5LO-deficient and MK886-
pretreated mice. MK571 also prevented the impaired gas
exchange induced by HVt. We previously observed that pre-
treatment with MK571 prevented the impairment of gas ex-
change and loss of HPV induced by endotoxin challenge.
Although not measured directly in this study, it is probable that
MK571 preserves systemic oxygenation in mice subjected to
HVt ventilation, at least in part, by maintaining the ability of the
pulmonary vasculature to vasoconstrict in response to hypoxia.
These observations suggest that activation of the cysLT1 receptor
contributes to the pathogenesis of VILI. Interestingly, as pre-
viously reported for endotoxin challenge (27), treatment with
MK571 did not reduce pulmonary neutrophil accumulation in
BALF associated with HVt ventilation, suggesting that pulmo-
nary neutrophil infiltration alone is not sufficient to cause VILI.
The cysLT1 receptor has been detected in pulmonary smooth
muscle cells as well as in circulating blood leukocytes (20), and
it has been recently suggested that cysLTs may act as activating
ligands for peripheral leukocytes (43). It is conceivable that
MK571 may partially prevent the development of VILI by inhib-
iting the activation of leukocytes recruited to the lung by HVt
ventilation. The incomplete reduction of pulmonary plasma pro-
tein extravasation after HVt ventilation in 5LO-deficient mice
and in MK886- and MK571-treated wild-type mice suggests that
additional LT-independent mechanisms also contribute to im-
paired alveolar–capillary membrane function during HVt venti-
lation (7, 9, 44).
VILI significantly contributes to the mortality associated with
ARDS (45). In a recent randomized controlled clinical trial (46),
the use of LVt ventilation in patients with ARDS led to a 22%
reduction of mortality in comparison with a traditional HVt
ventilatory strategy. Despite improvements in care, themortality
rate of patients affected by ARDS remains approximately 30 to
40% (45). Moreover, during acute lung injury, because of the
inhomogeneity of the disease, even LVt ventilation may result
in high levels of stretch applied to local lung regions, thereby
further worsening lung injury (47). A common feature of ARDS
is severe arterial hypoxemia, which is attributed in part to an
attenuation of the vasoconstrictor response to hypoxia (HPV)
(6). The current study demonstrated in mice that mechanical
ventilation at HVt impairs HPV. Moreover, interruption of the
5LO pathway attenuated VILI and prevented the impairment
of HPV associated with HVt ventilation, suggesting a critical
role of LTs, especially cysLTs, in the pathogenesis of murine
VILI. If observations in mice may be extrapolated to humans,
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these findings suggest that pharmacologic inhibition of LT pro-
duction or LT receptor blockade may prevent the injurious ef-
fects ofmechanical ventilation on the efficiency of the respiratory
system and HPV in patients with acute respiratory failure.
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